Table 4.

Correlation between ccfHPV16 detection and HPV16 integration status for ccfHPV^neg and ccfHPV^pos primary oncology patients (N = 37).

HPV16 integration status a	ccfHPVneg primary oncology (N = 5) b , n (%)	ccfHPVpos primary oncology (N = 32) c , n (%)
Complete integration	4 (80.0)	9 (28.1)	P = 0.04 d
Non‐integration	1 (20.0)	23 (71.9)

^aHPV16 integration status defined as follows; complete integration: ≥ 2 consecutive amplicons with 0 reads; non‐integration: < 2 consecutive amplicons with 0 reads.

^bccfHPV^neg primary oncology patients with HPV16‐related cancer.

^cccfHPV^pos primary oncology patients with HPV16‐related cancer.

^dFisher's exact test.